TABLE 3

Factors Associated With Outcomes in Adjusted Cox Proportional Hazards Models

VariableDuration of Continuous AlbuterolTime to q4 AlbuterolHospital LOS
HR (95% CI)PHR (95% CI)PHR (95% CI)P
Magnesium use0.54 (0.37–0.77)<.0010.38 (0.26–0.55)<.0010.41 (0.28–0.60)<.001
Ipratropium use0.97 (0.58–1.62).8960.56 (0.33–0.94).0270.78 (0.47–1.30).340
Female0.81 (0.61–1.07).1410.92 (0.69–1.24).5971.01 (0.75–1.35).941
African American0.6 (0.27–1.31).2010.86 (0.39–1.86).6940.78 (0.35–1.70).525
White0.49 (0.22–1.12).0910.7 (0.31–1.59).3930.54 (0.23–1.25).149
Unknown race0.56 (0.25–1.27).1640.78 (0.34–1.79).5650.75 (0.33–1.72).502
Location: PICU0.87 (0.56–1.35).5431.64 (1.05–2.55).0281.65 (1.06–2.58).026
Respiratory failure0.86 (0.52–1.42).5570.54 (0.33–0.90).0170.67 (0.40–1.12).129
  • HRs <1 signify longer time until intermittent albuterol, longer time until q4 albuterol, and longer time until hospital discharge, respectively. These analyses were adjusted for sex, race and/or ethnicity, treatment location, and respiratory failure.